Monoclonal Antibodies in Therapy of Solid Tumors

David M. Heimann, Louis M. Weiner

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Monoclonal antibodies have become increasingly used therapeutic agents for the treatment of solid cancer. Many are now being tested as components of adjuvant or first-line therapies to assess their efficacy in improving or prolonging survival. Selected unconjugated antibodies can exert clinically significant antitumor effects in many cancers. Antibody conjugates have been used to deliver toxic principles, such as radioactive particles, chemotherapeutic agents, and catalytic toxins, with increasing success in clinical trails.

Original languageEnglish
Pages (from-to)775-792
Number of pages18
JournalSurgical Oncology Clinics of North America
Issue number4
StatePublished - Oct 2007
Externally publishedYes


Dive into the research topics of 'Monoclonal Antibodies in Therapy of Solid Tumors'. Together they form a unique fingerprint.

Cite this